EVA Pharma’s roots stretch back over a hundred years.

thumbnail_Pharmacy.jpeg

Pharmacy.jpeg

Our History

Our experienced leadership team keeps us on track.

thumbnail_Find_Out_More_Leaders.png

Find_Out_More_Leaders.png

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

thumbnail_shutterstock_1578659503@2x.png

shutterstock_1578659503@2x.png

Life at EVA Pharma

Are you a Journalist or Media Representative and need information about us? Please feel free to get in touch with our PR Team

thumbnail_pexels-kaboompics-com-6335@2x.png

pexels-kaboompics-com-6335@2x.png

Media Contact

Event

thumbnail_EVAxCPHIQ12026_website-trial1600x1200 (1).png

EVAxCPHIQ12026_website-trial1600x1200 (1).png

By combining state-of-the-art R&D, including mRNA and AI capabilities, with localized production, EVA Pharma ensures sustainable access to critical medicines.

CPHI Middle East

thumbnail_EVAxWHX-Dubai_Ann_Q10126EVA-Website.png

EVAxWHX-Dubai_Ann_Q10126EVA-Website.png

EVA Pharma is participating in WHX Dubai (formerly Arab Health), one of the region’s leading healthcare exhibitions

WHX Dubai

thumbnail_EVAxMIS_Ann-01-web-eng (1).png

EVAxMIS_Ann-01-web-eng (1).png

KSA Saudi Made localization Saudization Empowering health research and development

Saudi Made 2025

thumbnail_hero-section-ss.jpg

hero-section-ss.jpg

CPHI Worldwide 2025 Frankfurt EVA Pharma is a global healthcare company operating across 70+ countries, dedicated

CPHI Worldwide 2025

·&nbsp; &nbsp;Riyadh, Saudi Arabia —&nbsp;23 Safar 1447 | August 17, 2025,&nbsp;EVA Pharma&nbsp;one of the fastest-growing pharmaceutical companies in the Middle East and Africa,&nbsp;signed a memorandum of understanding with the Riyadh First Health Cluster, aiming to collaborate in training and scientific research, with a particular focus on clinical research. This step reflects the commitment of both parties to advancing the healthcare sector and strengthening research capabilities in Saudi Arabia.
Dr. Amgad Talaat, Regional Director of EVA Pharma in Saudi Arabia, stated that this cooperation is designed to empower healthcare professionals within the Cluster to acquire the necessary research skills, thereby enhancing the Kingdom’s medical research infrastructure.
Dr. Talaat emphasized EVA Pharma’s strong commitment to supporting education and professional development across the Kingdom. “At EVA Pharma, we don’t limit our contribution to industry and research infrastructure—we also strive to create practical learning opportunities for national talent,” he noted. This commitment was recently demonstrated through EVA Pharma’s student training program, which enabled two Saudi pharmacy students to visit the company’s advanced R&amp;D centers in Egypt for hands-on training in the latest pharmaceutical development and manufacturing technologies. 
Talaat added: “We believe that investing in people is the cornerstone of building any healthcare system. EVA Pharma is fully committed to leveraging its expertise and resources to support Saudi talent, in full alignment with the ambitions of Saudi Vision 2030.”
--End of Press Release--
&nbsp;About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holding, one of the fastest-growing healthcare companies in the Middle East and Africa while operating in more than 70 countries worldwide. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.
For more information, please visit: <a href="https://www.evapharma.com/en-SA">https://www.evapharma.com/en-SA</a> or follow us on <a href="https://twitter.com/EVAPharma_MEA">X</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/evapharma_middle_east/" target="_blank" rel="noopener">Instagram</a> &nbsp;
&nbsp;
<div style="mso-element: endnote-list;">
<div id="edn1" style="mso-element: endnote;"></div>
</div>

thumbnail_EVAxrfhc-01.png

EVAxrfhc-01.png

Press Release

“Riyadh First Health Cluster” and “EVA Pharma” Sign MoU in the fields of Training, Research, and National Talent Development

GOLDEN, Colo., CAIRO, Egypt — October 30, 2025 —&nbsp;<a href="https://pharmajet.com/">PharmaJet</a>®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Distribution Agreement with&nbsp;<a href="https://atr-eg.com/our-history/">ATR</a>, an affiliate to&nbsp;<a href="https://www.evapharma.com/en">EVA Pharma</a>, the leading pharmaceutical company driving healthcare innovation and access across the Middle East and Africa.&nbsp;The agreement, signed in Frankfurt at the&nbsp;CPHI meeting&nbsp;on October 30, 2025, includes provisions for Tropis distribution, technology transfer, and manufacturing.
&nbsp;
The aim of the collaboration is to increase needle-free access within Egypt and regionally while broadening Egypt’s manufacturing capabilities. PharmaJet’s&nbsp;<a href="https://pharmajet.com/tropis-id/">Tropis®</a>&nbsp;intradermal needle-free delivery offers several strategic advantages for Egypt including substantial polio immunization cost savings1, reduced vaccine hesitancy2,3, increased coverage3, and the potential for medical technology regional manufacturing. The signing follows the&nbsp;<a href="https://pharmajet.com/pharmajet-enters-into-mou-agreement-with-egyptian-upa-and-eva-pharma-to-provide-needle-free-delivery-for-routine-immunization-in-egypt/">July 2025 Memo of Understanding (MOU)</a>&nbsp;that was signed between PharmaJet, Egypt’s Unified Procurement Agency (UPA) and EVA Pharma, which outlined plans for how UPA could incorporate Tropis into its portfolio.
&nbsp;
The introduction of Tropis into immunization programs supports Egypt’s&nbsp;“<a href="https://www.egypttoday.com/Article/1/125918/Egypt-set-to-launch-1000-Golden-Days-initiative-to-develop">1000 Golden Days"</a>&nbsp;initiative which was launched to support the health and development of families during the critical period from conception to a child's second birthday. The collaboration will enable total immunization cost reduction and improved acceptability of polio vaccinations. Longer-term, the Tropis manufacturing and other needle-free product development initiatives may expand the benefits to vaccination against other infectious agents and improved pandemic preparedness.
&nbsp;
EVA Pharma is a leading pharmaceutical and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, distributing, and promoting pharmaceutical products. “This collaboration puts children first,” said Riad Armanious, CEO of EVA Pharma. “We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably.”
&nbsp;
“We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery,” said Paul LaBarre, Senior Vice President of Business Development for PharmaJet. “This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle-free intradermal vaccine delivery into routine immunization programs in Egypt and beyond.”
&nbsp;
Refer to Instructions for Use to ensure safe injections and to review risks.&nbsp;
&nbsp;
1&nbsp;Data on file
2&nbsp;Soonawala, D et al,&nbsp;<a href="https://www.sciencedirect.com/science/article/abs/pii/S0264410X13007640?via%3Dihub">Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults,</a>&nbsp;Vaccine,&nbsp;Volume 31, Issue 36,&nbsp;12 August 2013, Pages 3688-3694
3&nbsp;Mohan, D et al,&nbsp;<a href="https://www.mdpi.com/2076-393X/13/5/533">Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial</a>&nbsp;, Vaccines,16 May 2025, 13(5), p.533
&nbsp;
&nbsp;
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use.&nbsp;<a href="https://pharmajet.com/tropis-id/">Tropis®&nbsp;&nbsp;ID</a>&nbsp;has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit&nbsp;<a href="https://www.pharmajet.com/">https://www.pharmajet.com</a>&nbsp;or contact PharmaJet&nbsp;<a href="https://pharmajet.com/contact/">here</a>. Follow us on&nbsp;<a href="https://www.linkedin.com/company/pharmajet-inc/">LinkedIn</a>.
&nbsp;
&nbsp;
About EVA Pharma&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;For more information, please visit:&nbsp;<a href="https://www.evapharma.com/en">https://www.evapharma.com/en</a>.
&nbsp;

thumbnail_IMG_5960_optimized_600.jpeg

IMG_5960_optimized_600.jpeg

PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt

&nbsp;
<span style="font-style: normal; font-variant: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;·<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With investments exceeding SAR 450 million, EVA Pharma is moving steadfastly with the launch of a 50+ thousands sqm research &amp; manufacturing complex in the heart of Saudi Arabia.
·<span style="font-style: normal; font-variant: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The complex will serve a variety of therapeutic areas, with more than 150 pharmaceutical products covering the fields of oncology, immunosuppressants, vaccines, biologics and a wide range of treatments that require advanced technologies.
·<span style="font-style: normal; font-variant: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The MoU with the Ministry of Investment emphasizes a crucial collaboration between the private sector and the government to build Saudi Arabia’s bio-manufacturing market capabilities.
Riyadh, Saudi Arabia — December 13, 2023, EVA Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA), solidifies its unwavering dedication to the Saudi market with a series of monumental achievements. This includes the groundbreaking ceremony for the state-of-the-art pharmaceutical research and manufacturing complex in Sudair and the inauguration of its Riyadh office. Additionally, EVA Pharma proudly affirms its strategic partnership with the Ministry of Investment through the signing of a MoU as part of the ceremony.
The industrial complex aims to become a center of gravity for pharmaceutical manufacturing in the region with sustainable accessibility for innovative healthcare solutions. It will comprise an R&amp;D center and five pharmaceutical factories, including one for immunosuppressants and oncology products, another facility for biologics, a vaccines production unit, in addition to a facility for oral dosage forms like DPIs, Bi-layer tablets, and ODT. The complex will produce over 150 pharmaceutical products, spanning various therapeutic areas and addressing the most demanding health challenges in the Kingdom.
"On the personal level &amp; as a representative of the 5000 people in EVA Pharma we feel very blessed to be here &amp; we feel very excited about what we can bring to Saudi patients &amp; to Arab patients in the next months &amp; years. This assembly of manufacturing facilities will bring cutting-edge technologies to Saudi, so that Saudi can reach the healthcare independence that it aspires to have”; said Riad Armanious, CEO of EVA Pharma.
“This is a project that has had a tremendous support in every milestone and as we break-ground today for this first-of-its-kind cluster in the Kingdom, we will maintain our momentum &amp; we will have production in the very near future. We feel that we are doing the right thing, in the right time and in the right place. 
We are grateful for the Saudi support, thank you for all those who have helped us, inspired us, &amp; we promise, we’re here to collaborate &amp; we’re here to bring cutting edge technologies to meet unmet patients’ needs.”
EVA Pharma's strategic move into Saudi Arabia underscores its dedication to meeting unmet patient needs and marks its initial steps in the Saudi market through substantial local investments. By establishing a pharmaceutical research and manufacturing complex in Sudair, EVA Pharma aims to contribute to the Kingdom's Vision 2030 healthcare goals of increasing the production of local pharmaceutical products. The health sector transformation program aims to raise the private sector's contribution to 50%, a substantial increase from the current 11%.
The Sudair complex is designed by German consultancy IO, the complex embodies a green circular economy approach. The design of the complex not only pays homage to cultural roots but also strategically minimizes heat gain, thereby significantly reducing its carbon footprint. Contributing to the overall reduction of environmental impact, the complex will incorporate solar panels, on-site water recycling and waste treatment systems. Showcasing EVA Pharma’s environmentally conscious approach that aligns seamlessly with Saudi Arabia's vision for a greener and more sustainable future.
&nbsp;
About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals in 40+ countries, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
&nbsp;

thumbnail_MoU-MISA-EVA-Pharma-test.png

MoU-MISA-EVA-Pharma-test.png

EVA Pharma Announces Groundbreaking of its Research & Manufacturing Complex in Sudair and Unveils Revolutionary Partnership with the Ministry of Investment

Press Release

“Riyadh First Health Cluster” and “EVA Pharma” Sign MoU in the fields of Training, Research, and National Talent Development

2025-08-16

Top News

Press Release

2025-08-16

Press Release

2025-10-29

Press Release

2023-12-12

Top News

Press Release

“Riyadh First Health Cluster” and “EVA Pharma” Sign MoU in the fields of Training, Research, and National Talent Development

2025-08-16

© 2026 Eva Pharma All Rights Reserved